Skip to main content

Table 3 Characteristics of fasting1 versus non-fasting participants by sex, the HUNT 2 study

From: Age-specific prevalence of the metabolic syndrome defined by the International Diabetes Federation and the National Cholesterol Education Program: the Norwegian HUNT 2 study

 

Men

Women

 

Fasting1

Non fasting

 

Fasting1

Non fasting

 

N (%)

5101

(17.0%)

24,914

(83.0%)

 

5105

(15.2%)

28,480

(84.8%)

 

Categorical measures, % (95% CI)

  

Odds ratio

  

Odds ratio

IDF-proxy for metabolic syndrome2

13.8

(12.8–14.7)

14.4

(14.0–14.9)

1.05

(0.97–1.15)

14.8

(13.9–15.8)

13.8

(13.4–14.2)

0.92

(0.85–1.00)

ATP-proxy for metabolic syndrome3

5.8

(5.2–6.5)

5.8

(5.5–6.1)

1.00

(0.88–1.14)

9.8

(8.9–10.6)

9.0

(8.7–9.4)

0.92

(0.83–1.02)

Type 2 diabetes

1.6

(1.2–1.9)

1.9

(1.7–2.0)

1.18

(0.93–1.49)

2.0

(1.6–2.4)

1.6

(1.5–1.8)

0.81

(0.65–1.01)

Antihypertensive medication

10.3

(9.5–11.1)

10.3

(9.9–10.6)

1.00

(0.90–1.10)

13.1

(12.2–14.0)

11.6

(11.2–12.0)

0.87*

(0.80–0.96)

Continuous measures, means (95% CI)

  

Mean z-score diff.

  

Mean z-score diff.

Age, y

48.4

(48.0–48.9)

50.0

(49.8–50.2)

0.093*

49.4

(48.9–49.8)

50.2

(50.0–50.4)

0.048*

Systolic blood pressure, mm Hg

140.4

(139.8–140.9)

140.0

(139.7–140.2)

-0.022

137.3

(136.6–137.9)

135.8

(135.5–136.1)

-0.062*

Diastolic blood pressure, mm Hg

83.4

(83.0–83.7)

81.7

(81.6–81.9)

-0.138*

80.0

(79.6–80.3)

78.7

(78.6–78.9)

-0.101*

Waist circumference, cm

92.2

(91.9–92.5)

91.9

(91.8–92.0)

-0.028

82.0

(81.7–82.4)

81.5

(81.4–81.6)

-0.050*

HDL cholesterol, mmol/L

1.26

(1.25–1.27)

1.24

(1.23–1.24)

-0.063*

1.50

(1.49–1.52)

1.49

(1.49–1.50)

-0.029

Triglycerides, mmol/L

1.73

(1.70–1.76)

2.02

(2.01–2.04)

0.240*

1.44

(1.42–1.47)

1.59

(1.58–1.60)

0.153*

Glucose, mmol/L

5.30

(5.27–5.33)

5.60

(5.58–5.62)

0.185*

5.20

(5.17–5.23)

5.41

(5.40–5.43)

0.150*

  1. HUNT, the Nord-Trøndelag Health study; CI, confidence interval; IDF, the International Diabetes Federation; ATP, the National Cholesterol Education
  2. Program-Adult Treatment Panel III; HDL, high-density lipoprotein.
  3. *P < 0.05.
  4. 1Four to nine hours or more since the last meal.
  5. 2IDF-proxy for metabolic syndrome defined as IDF-central obesity plus any two of three components (low HDL cholesterol, high blood pressure or treatment for previously diagnosed hypertension, or previously diagnosed type 2 diabetes).
  6. 3ATP-proxy for metabolic syndrome defined as any three of four components (ATP III-defined central obesity, low HDL cholesterol, high blood pressure or treatment for previously diagnosed hypertension, or previously diagnosed type 2 diabetes).
Back to article page

BMC Public Health

ISSN: 1471-2458

Contact us